Article
Rates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in Brazil
Registro en:
DREXLER, J. F. et al. Rates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in Brazil. Journal of Clinical Microbiology, v. 45, n. 6, p. 2061–2063, 2007.
0095-1137
10.1128/JCM.00136-07
Autor
Drexler, Jan Felix
Luna, Luciano Kleber de Souza
Pedroso, Celia
Sampaio, Diana Brasil Pedral
Queiroz, Artur Trancoso Lopo de
Brites, Carlos
Martins Netto, Eduardo
Drosten, Christian
Resumen
Brazilian Ministry of Health grants CFA 273/04 and CFA 238/05. The Bernhard Nocht Institute
receives funding from the German Ministry of Health for operating the National Reference Centre for Tropical Infectious Diseases. L. K. de Souza Luna is receiving a scholarship from the Brazilian National
Council of Technological and Scientific Development CNPQ We examined failures of commercial human immunodeficiency virus type 1 (HIV-1) viral load assays of 1,195 plasma samples from Brazilian patients. Assay failure was assumed for samples in which the virus was undetectable by commercial assay but which tested positive by real-time reverse transcription-PCR of the HIV-1 long terminal repeat (LTR) region or if the viral load differed by >2 log10 from that determined by LTR assay. Failure rates for Bayer Versant bDNA 3.0, Roche Amplicor Monitor v1.5, and bioMerieux NucliSens QT were 0.68, 0.47, and 4.33%, respectively. NucliSens may be inadequate for use in Brazil.